1. Home
  2. BKV vs CDNA Comparison

BKV vs CDNA Comparison

Compare BKV & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BKV Corporation

BKV

BKV Corporation

HOLD

Current Price

$22.95

Market Cap

2.9B

Sector

Energy

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$54.33

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKV
CDNA
Founded
2015
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical Specialities
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.6B
IPO Year
2022
2007

Fundamental Metrics

Financial Performance
Metric
BKV
CDNA
Price
$22.95
$54.33
Analyst Decision
Strong Buy
Buy
Analyst Count
9
6
Target Price
$34.22
$28.00
AVG Volume (30 Days)
2.0M
1.0M
Earning Date
05-07-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
199.00
N/A
EPS
1.11
2.13
Revenue
$893,781,000.00
$48,324,000.00
Revenue This Year
$69.39
$16.01
Revenue Next Year
$9.45
$11.31
P/E Ratio
$20.66
$25.21
Revenue Growth
47.85
18.93
52 Week Low
$20.08
$13.95
52 Week High
$32.81
$55.16

Technical Indicators

Market Signals
Indicator
BKV
CDNA
Relative Strength Index (RSI) 39.86 68.92
Support Level N/A $45.74
Resistance Level $27.55 N/A
Average True Range (ATR) 1.04 2.02
MACD -0.24 -0.03
Stochastic Oscillator 13.62 81.33

Price Performance

Historical Comparison
BKV
CDNA

About BKV BKV Corporation

BKV Corp is a growth-driven energy company focused on the development of natural gas-producing assets, the ownership and operation of natural gas-fired power generation assets, and selective accretive acquisitions. The company's core businesses are the production of natural gas and the generation of natural gas-fired power from its owned and operated assets, supported by a closed-loop plan, enabled by its upstream, midstream, power, and CCUS businesses.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: